Overview

• Researchers discovered that blocking the mitochondrial carrier protein Ant2 rewires CD8+ T cell energy metabolism.
• Ant2-deficient T cells in mouse models exhibited enhanced stamina, faster replication and heightened tumor-killing efficacy.
• Small-molecule inhibitors reproduced the genetic Ant2 deficiency, indicating a viable path toward clinical therapies.
• Published in Nature Communications on May 8, the study paves the way for early-phase human trials on safety, dosing.
• The work was led by Omri Yosef and Prof. Michael Berger in collaboration with Magdalena Huber and Eyal Gottlieb across three continents.